These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25287518)

  • 21. Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    Brannon Traxler L; Martin ML; Kerber AS; Bellcross CA; Crane BE; Green V; Matthews R; Paris NM; Gabram SG
    Ann Surg Oncol; 2014 Oct; 21(10):3342-7. PubMed ID: 25047474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI screening in a clinic population with a family history of breast cancer.
    Yu J; Park A; Morris E; Liberman L; Borgen PI; King TA
    Ann Surg Oncol; 2008 Feb; 15(2):452-61. PubMed ID: 18026801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    Mann RM; Bult P; van Laarhoven HW; Span PN; Schlooz M; Veltman J; Hoogerbrugge N
    Eur J Radiol; 2013 Sep; 82(9):1416-22. PubMed ID: 23567481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype.
    Heikkinen T; Kärkkäinen H; Aaltonen K; Milne RL; Heikkilä P; Aittomäki K; Blomqvist C; Nevanlinna H
    Clin Cancer Res; 2009 May; 15(9):3214-22. PubMed ID: 19383810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
    Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
    J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
    Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM
    Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
    Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
    Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing.
    Erdahl LM; Boughey JC; Hoskin TL; Degnim AC; Hieken TJ
    Ann Surg Oncol; 2016 Jan; 23(1):72-7. PubMed ID: 26065870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Francis W; Halliday D; Royer R; Zhang S; Li S; Thompson I; Donenberg T; Hurley J; Akbari MR; Narod SA
    Clin Genet; 2016 Mar; 89(3):328-31. PubMed ID: 25920394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
    Arun B; Vogel KJ; Lopez A; Hernandez M; Atchley D; Broglio KR; Amos CI; Meric-Bernstam F; Kuerer H; Hortobagyi GN; Albarracin CT
    Cancer Prev Res (Phila); 2009 Feb; 2(2):122-7. PubMed ID: 19174581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
    Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
    Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychological distress related to BRCA testing in ovarian cancer patients.
    Bjørnslett M; Dahl AA; Sørebø Ø; Dørum A
    Fam Cancer; 2015 Dec; 14(4):495-504. PubMed ID: 25980896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.